Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Medigen Vaccine Biologics's shares outstanding for the quarter that ended in Dec. 2025 was 328.7 Mil.
Medigen Vaccine Biologics's quarterly shares outstanding
stayed the same
from Sep. 2025 (328.7 Mil) to Dec. 2025 (328.7 Mil).
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Medigen Vaccine Biologics Shares Outstanding (EOP) Related Terms
Medigen Vaccine Biologics Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Medigen Vaccine Biologics's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6547 vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison
For the Biotechnology subindustry, Medigen Vaccine Biologics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Vaccine Biologics Shares Outstanding (EOP) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Medigen Vaccine Biologics's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 328.7 Mil mean?
Medigen Vaccine Biologics (ROCO:6547) has a Shares Outstanding (EOP) of 328.7 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Medigen Vaccine Biologics and its competitors.
Is Medigen Vaccine Biologics' Shares Outstanding (EOP) too high?
Medigen Vaccine Biologics' current Shares Outstanding (EOP) is 328.7 Mil. Overall, Medigen Vaccine Biologics has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Shares Outstanding (EOP) compare to VRTX and REGN?
Medigen Vaccine Biologics' Shares Outstanding (EOP) of 328.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Medigen Vaccine Biologics and its competitors. Medigen Vaccine Biologics's current Shares Outstanding (EOP) is 328.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.34, compared to a current price of NT$47.40 — trading 32.6% below its estimated fair value. The current Shares Outstanding (EOP) is 328.7 Mil. Medigen Vaccine Biologics' overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Shares Outstanding (EOP) is 328.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued.
The current stock price of NT$47.40 is trading 32.6% below its estimated GF Value™ of NT$70.34.
GuruFocus considers Medigen Vaccine Biologics to be Possible Value Trap.
Key valuation signals for ROCO:6547:
Shares Outstanding (EOP): 328.7 Mil
GF Value™: NT$70.34 vs. price of NT$47.40 (32.6% below fair value)
No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
66GF Score
Get the complete analysis for ROCO:6547
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6547 has been successfully added to your 
